Scinai Immunotherapeutics (SCNI) Asset Utilization Ratio (2026)
Scinai Immunotherapeutics' (SCNI) quarterly Asset Utilization Ratio came in at 0.1 in Q2 2026, down 1.42% quarter-over-quarter from 0.1 in Q1 2026.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) Asset Utilization Ratio (2026) Analysis & Trends
Scinai Immunotherapeutics has disclosed Asset Utilization Ratio across 1 years of filings, most recently posting 0.1 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio changed N/A year-over-year to 0.1; the TTM figure through Jun 2026 stood at 0.1 (changed N/A YoY), while the FY2025 annual figure was 0.19, up 347.72% from the prior year.
- Asset Utilization Ratio came in at 0.1 for Q2 2026 at Scinai Immunotherapeutics, down from 0.1 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.1 in Q1 2026 to a low of 0.1 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn | 0.10 |